全球心臟節律器市場：市場規模、佔有率和趨勢分析（2025-2032 年）

全球心臟心律調節器市場報告

2025年全球心臟節律器市場規模為31.6億美元。在預測期內，該市場預計將以6.5%的複合年成長率成長，到2032年將超過49億美元。

這份關於全球心臟節律器市場的綜合報告涵蓋了單室調節器和雙腔心律調節器，每個類別都包含經靜脈植入式和無導線植入式兩種型號。報告的結構和內容順序與附件中的範例文件相同，並根據全球心臟心律調節器市場的特定趨勢進行了調整。

本報告詳細分析了銷售量、平均售價、手術例數、市場規模和成長趨勢，包括至2032年的預測數據和至2022年的歷史數據。報告中還涵蓋了市場促進因素和限制因素、近期併購、公司概況、產品系列和主要競爭對手。因此，本報告全面整體情況了心臟節律管理領域中這一龐大且不斷發展的細分市場。

心律調節器市場持續受益於龐大且穩定的患者群體，因為對於患有傳導障礙和症狀性心搏過緩的患者而言，心律調節器治療仍然至關重要。同時，這一領域不再僅限於標準的經靜脈植入裝置。無導線心律調節器、傳導式心律調節器、人工智慧診斷和遠端監測等方面的創新正在改變醫生的預期和市場的經濟結構。

目前，最顯著的變化之一是高階心律調節器平台的崛起。單腔無導線心律調節器已開始在幾個關鍵市場取代傳統的單腔系統，而標準雙腔和無導線雙腔心律調節器的市場佔有率也在穩步成長。這項轉變意義重大，因為它為原本可能面臨更嚴重商品化和價格壓力的市場增添了價值。高階技術有助於減緩價格下降的速度，並為這個在全球範圍內仍然具有重要臨床意義的領域創造新的成長機會。

市場概覽

全球心臟節律器市場包括用於治療心搏過緩緩和傳導系統紊亂的植入式心臟裝置，這些裝置透過輸送電脈衝來維持正常的心率。多年來，這些裝置一直是心臟節律管理的核心，並且仍然是心血管醫療技術領域最成熟的治療類別之一。

從歷史上看，經靜脈單腔和雙腔心律調節器系統一直主導著這個市場。這些設備目前仍佔全球需求的很大一部分，並在已開發市場和新興市場繼續廣泛使用。然而，這一領域正在迅速發展。新一代設備正在改變醫生行醫的方式，市場也日益分化，成熟的經靜脈心律調節器系統與新型高階心律調節器技術之間呈現出明顯的兩極化趨勢。

無導線心律調節器是這種轉變最明顯的例證之一。這類裝置透過取消導線和囊袋，減輕了硬體負擔，從而降低了某些患者併發症的風險。單腔心律調節器領域尤其明顯地體現了無導線心律調節器的普及，在某些市場，它們已經開始削弱標準單腔心律調節器的市場佔有率。隨著雙腔無導線技術的日益普及，市場正進一步向「混合模式」轉變，高階系統正從傳統植入手中奪取市場佔有率。

此外，市場與數位基礎設施的連結日益緊密。遠端監測、雲端數據平台和更先進的診斷軟體正在改善後續工作流程，並提升心律調節器治療的整體提案。隨著醫療系統努力高效管理日益龐大的患者群體，這些功能在採購決策和醫生採納過程中變得愈發重要。

總體而言，全球心律調節器市場仍然是一個龐大且穩定的治療市場，但目前的成長不僅受植入數量的簡單影響，還受技術升級、高階設備的普及以及心律調節器治療的逐步現代化的影響。

市場促進因素

新技術

技術進步仍然是全球心臟心律調節器需求的最強驅動力之一。傳導心律調節器是關鍵領域之一。由於希氏束心律調節器和左束支區域心律調節器比傳統的右心室心律調節器更能支持生理性心室激活，因此臨床醫生擴大採用它們。這種轉變意義重大，因為它正在改變高階醫療機構的植入實踐，並促進更多專業化心律調節器設備的使用。

2023年5月，百多力（Biotronik）首款專為傳導起搏設計的心律調節器產品線獲得CE核准，印證了這一趨勢的商業性重要性。隨著製造商不斷推出針對傳導的專用導線和輸送系統，預計這一領域仍將是推動心律調節器市場成長的最強勁技術驅動力之一。

無導線起搏也是推動市場成長的主要動力。單腔無導線系統已展現出醫師積極採用心內起搏平台的意願，尤其是在植入過程更簡單且安全性數據可靠的情況下。隨著Micra AV和AVEIR DR等雙腔無導線系統的出現，市場正在進一步擴張。這些設備在心律調節器市場中屬於高階產品，擴大被感染風險高的患者、靜脈通路受限的患者或需要更複雜手術的患者所選擇。隨著醫生技術水平的提高和醫療保險報銷機制的日益完善，預計無導線心律調節器仍將是市場成長最強勁的引擎之一。

更長的電池續航時間和與核磁共振的兼容性持續推動市場成長。目前一代的設備在標準設定下通常預計可使用10年以上，這增強了醫生的信心，並減輕了重複更換手術的負擔。大多數新型設備預計都將與核磁共振有條件相容，從而消除了以往植入設備對未來可能需要進行影像檢查的患者的限制。

市場限制

市場飽和

全球心臟心律調節器市場的主要限制因素之一是已開發地區的市場飽和。在許多成熟的醫療體系中，心臟節律器的普及率已經很高，大多數明確需要心律調節器治療的患者都已經植入了心律調節器。這意味著手術數量的年度成長並非由初始植入量的顯著增加所驅動，而是主要由更換手術、患者年齡成長和技術升級所支撐。

這仍然足以支撐市場健康成長，尤其是在高階技術不斷擴張的背景下。然而，這意味著在許多已開發市場，種植總量不太可能大幅成長。這些地區的成長將更加漸進，並以價值主導。

商品化

商品化也是一個重要的阻礙因素，尤其是在標準經靜脈心律調節器領域。目前，大多數主要製造商生產的經靜脈起搏系統在性能、耐用性和基本功能方面都大同小異。這使得產品差異化難以實現，並對價格構成下行壓力，尤其是在受競標、大規模醫院集團和集中採購模式影響的市場中。

雖然無導線系統構成了一個高階細分市場，有助於緩解這個問題，但經靜脈心律調節器市場的大部分仍然是高銷量、低利潤的類別。這限制了定價的柔軟性，迫使製造商依靠服務、品牌信任、部署記錄和細微的功能差異，而不是顯著的產品差異化。

記起

近期的召回事件也給市場帶來了進一步的壓力。過去幾年一系列引人注目的心律調節器召回事件導致監管機構加強了審查，醫生也提高了警覺。波士頓科學公司宣布將於2024年和2025年對其ACCOLADE系列的部分產品進行多項I類召回，這將影響更換工作並增加監控的複雜性。雅培公司也宣布將於2024年和2025年對其AVEIR無導線起搏系統進行II類召回並採取安全措施，這些措施主要透過軟體更新和編程流程的修訂來解決。

雖然這些事件不會改變長期對心律調節器治療的需求，但它們會透過加強監管、提高醫生的謹慎態度以及使可靠性至關重要的這一領域的市場認知變得複雜，從而造成短期壓力。

市場覆蓋範圍和數據範圍

定量範圍

市場規模、市佔率、市場預測、市場成長率、銷售量、平均售價。

定性研究範圍

市場促進因素和限制因素、成長趨勢、近期併購、公司概況、產品系列和主要競爭對手。

目標期

基準年：2025 年，歷史資料截至 2022 年，預測至 2032 年。

包含的資料類型

銷售量、平均售價、治療次數、市場規模和成長趨勢。

本報告旨在透過將詳細的市場數據與技術採用和市場結構的實際分析相結合，為策略規劃、競爭基準分析和市場定位提供支援。

目標市場及區隔

• 本報告涵蓋全球心臟節律器市場，並進一步細分為以下幾個部分：

單腔心律調節器市場

此部分不僅包括傳統的經靜脈單心室節律器，還包括單心室無導線心律調節器。

雙腔心律調節器市場

這部分不僅包括傳統的經靜脈雙潤滑系統，還包括新興的無導線雙潤滑心律調節器。

每個細分市場均根據銷售量、平均售價和市場總值進行分析，並包含截至 2032 年的預測和截至 2022 年的歷史數據。這種細分體現了市場中心室配置之間以及傳統心律調節器和無導線心律調節器之間的關鍵結構性分類。

競爭分析

預計到2025年，美敦力將在全球心臟心律調節器市場佔最大佔有率，並在所有主要細分市場中保持主導地位。該公司的優勢源於廣泛的臨床證據、醫生的高度認可以及包括Azure、Advisa MRI SureScan、Adapta和Atesta在內的豐富產品組合。美敦力憑藉其Micra系列產品在無導線心律調節器領域也保持著主導地位，該系列產品仍然是全球應用最廣泛的平台。憑藉大量的註冊數據、高部署率以及預計優異的電池性能，Micra仍然是推動美敦力持續保持市場領先地位的關鍵因素之一。此外，對生理起搏和延長設備壽命的持續投入進一步鞏固了公司的長期市場地位。

雅培在全球排名第二，憑藉其Assurity MRI和Endurity平台以及不斷擴展的無導線產品系列，保持著強勁的競爭力。 AVEIR VR無導線心律調節器的推出標誌著一個重要的里程碑，使雅培成為第二家進入無導線心律調節器市場的主要企業。此後，AVEIR DR雙腔無導線系統已成為關鍵的策略成長平台。作為首款實現心房和心室直接通訊的模組化雙腔無導線解決方案，雅培在心律調節器領域最重要的新興領域之一確立了穩固的地位。早期部署和不斷擴大的核准範圍印證了AVEIR DR將顯著推動雅培未來市場佔有率成長的觀點。

波士頓科學公司在全球市佔率排名第三。其心律調節器產品系列包括相容於磁振造影（MRI）的系統，例如 ACCOLADE 和 ESSENTIO，以及傳統的心律調節器平台，例如 VITALIO、ADVANTIO 和 INGENIO。雖然波士頓科學公司目前尚未進軍無導線心律調節器市場，但它在傳統的經靜脈心律調節器領域仍然佔著重要地位，並透過增強診斷功能、提高設備耐用性以及更好地支持生理性起搏策略，不斷改進產品系列。其傳統產品組合仍然是公司更廣泛的心臟復健管理（CRM）業務的重要組成部分。

技術和臨床趨勢

心律調節器市場最顯著的趨勢之一是無導線心律調節器的快速崛起。單腔無導線心律調節器已經從標準單室調節器奪取了市場佔有率，而雙腔無導線系統正在開闢一個新的高階成長領域。

傳導系統起搏是另一個大趨勢。希氏束起搏和左束支區域起搏正在幫助臨床實踐從傳統的右心室起搏轉向更符合生理的起搏方法，尤其適用於某些患者。

遠端監測在現代心臟節律器的價值提案中也發揮核心作用。心率和設備資料的自動傳輸能夠實現更有效率的後續觀察和更可靠的長期病患管理。

最後，軟體和診斷功能正變得越來越複雜。人工智慧驅動的分析、更完善的程式設計工具和更整合的數據平台，使得起搏系統對醫生和醫療保健系統都更有價值。

地區

本報告涵蓋全球調查區域，包括北美、歐洲、亞太地區、拉丁美洲以及中東和非洲。

本報告包含詳細的市場分析、市場區隔和預測數據，共 133 頁。

附錄：調查方法和縮寫詞彙表。

這份報告的意義

到 2032 年，全球心臟節律器市場最大的成長機會在哪裡？

無導線心律調節器和傳導式心律調節器改變市場結構的速度有多快？

遠端監控、電池續航時間和軟體改進將在未來設備的價值中發揮怎樣的作用？

市場飽和、商品化和採購壓力將如何影響標準經靜脈心律調節器的前景？

在經靜脈節律器和無導線心律調節器領域，哪家競爭者佔最有利的地位，這種優勢能在多大程度上持續下去？

供應商、投資者和策略團隊應該如何評估這個既成熟又不斷發展的客戶關係管理 (CRM) 市場中的機會？

iData Research 的「全球心臟心律調節器市場報告」透過詳盡的市場規模、定價分析、市場細分和競爭格局信息，解答了這些問題。利用這份報告，您可以與競爭對手進行基準比較，了解技術主導的成長，並在規模龐大且日益優質化的心臟心律調節器市場中製定策略。

目錄

圖表清單

調查方法

• 步驟 1：計劃啟動與團隊組建
• 步驟 2：準備資料系統並進行二次調查。
• 步驟 3：設計和準備訪談和調查問卷。
• 步驟 4：進行初步調查
• 步驟 5：調查與分析：建立基準估計值
• 步驟 6：市場預測與分析
• 步驟 7：辨識策略機遇
• 步驟 8：最終審核和市場推廣
• 步驟 9：客戶回饋與市場監測

全球關稅的影響

• 全球心臟心律調節器市場概覽
• 競爭分析
• 目標程式
• 目標市場
• 目標區域

介紹

• 經靜脈心律調節器
• 無導線心律調節器
• 心臟節律器技術進步
• 心律調節器的初始植入和更換

手術次數

• 心律調節器植入手術的所有技術
• 心臟節律器首次植入手術
• 心臟心律調節器置換手術
• 無導線心律調節器手術

市場概覽

• 按細分市場
• 按地區

市場分析與預測

• 整體心律調節器市場
• 標準單室調節器市場
• 無導線單室調節器市場
• 標準雙腔心律調節器市場
• 無導線雙腔心律調節器市場

促進因素和抑制因素

競爭性市佔率分析

簡稱

Global Pacemaker Market Report

The global pacemaker market was valued at $3.16 billion in 2025. Over the forecast period, the market is expected to grow at a CAGR of 6.5% to reach over $4.9 billion by 2032.

The full report suite on the global pacemaker market includes single-chamber pacemakers and dual-chamber pacemakers, with each category including both transvenous and leadless markets. This report follows the same structure and content order shown in the attached example document, adapted to the specific dynamics of the global pacemaker market .

This report provides detailed analysis of unit sales, average selling prices, procedure numbers, market size and growth trends, with forecasts through 2032 and historical data to 2022. It also includes market drivers and limiters, recent mergers and acquisitions, company profiles, product portfolios and leading competitors. The result is a structured view of a large and evolving segment within cardiac rhythm management.

The pacemaker market continues to benefit from a large and recurring patient base, since pacing therapy remains essential for patients with conduction disorders and symptomatic bradycardia. At the same time, the category is no longer defined only by standard transvenous implants. Innovation in leadless pacing, conduction system pacing, AI-supported diagnostics and remote monitoring is changing both physician expectations and the economic mix of the market.

One of the biggest current changes is the rise of premium pacing platforms. Single-chamber leadless pacemakers have already begun to displace conventional single-chamber systems in several major markets, while both standard and leadless dual-chamber devices are growing steadily. This shift is important because it adds value to a market that would otherwise face stronger commoditization and price pressure. Premium technologies are helping slow the pace of price erosion and are creating new growth opportunities in a category that remains clinically essential worldwide.

Market Overview

The global pacemaker market includes implantable cardiac devices used to manage bradycardia and conduction system disorders by delivering electrical impulses that maintain appropriate heart rhythm. These devices have long been a core part of cardiac rhythm management and remain one of the most established therapy categories in cardiovascular MedTech.

Historically, the market was dominated by transvenous single-chamber and dual-chamber systems. These devices still account for a large share of global demand and remain widely used across developed and emerging markets. However, the category is now evolving quickly. New generations of devices are reshaping physician practice, and the market is increasingly split between mature transvenous systems and newer premium pacing technologies.

Leadless pacing is one of the clearest examples of this transition. These devices reduce hardware burden by eliminating leads and pockets, which can lower complication risk in selected patients. Their adoption has been especially strong in single-chamber pacing, where they have already started to reduce the role of standard single-chamber devices in several markets. As dual-chamber leadless technology becomes more available, the market is moving further toward a mixed model in which premium systems take share from conventional implants.

The market is also increasingly tied to digital infrastructure. Remote monitoring, cloud-based data platforms and more advanced diagnostic software are improving follow-up workflows and strengthening the overall value proposition of pacing therapy. As healthcare systems try to manage larger patient populations more efficiently, these capabilities are becoming more important to purchasing decisions and physician adoption.

Overall, the global pacemaker market remains a large and dependable therapy market, but its current growth is being shaped less by basic implant volume alone and more by technology upgrades, premium device penetration and the gradual modernization of pacing practice.

Market Drivers

New Technologies

Technological advancement remains one of the strongest drivers of global pacemaker demand. One major area is conduction system pacing. Clinicians are increasingly adopting His bundle pacing and left bundle branch area pacing because these methods support more physiologic ventricular activation than traditional right ventricular pacing. This shift is meaningful because it is changing implant practice in high-volume centers and increasing the use of more specialized pacing tools.

Biotronik's CE mark approval in May 2023 for the first family of pacemakers designed specifically for conduction system pacing reinforced the commercial importance of this trend. As manufacturers continue introducing dedicated leads and delivery systems for conduction system targeting, this area is expected to remain one of the strongest technology-driven supports for pacing market growth.

Leadless pacing is another major driver. Single-chamber leadless systems have already shown that physicians are willing to adopt intracardiac pacing platforms when they offer a simpler implant profile and strong safety data. The emergence of dual-chamber leadless systems such as Micra AV and AVEIR DR expands the addressable market much further. These devices create a premium category within pacing and are increasingly selected for patients with elevated infection risk, limited venous access or more complex procedural considerations. As operator familiarity improves and reimbursement becomes more consistent, leadless pacing is expected to remain one of the most powerful growth engines in the market.

Longer battery life and MRI compatibility remain supportive drivers as well. Current-generation devices often deliver projected longevity of 10 years or more under standard settings, which increases physician confidence and reduces the burden of repeat replacement procedures. MRI conditional labeling is now expected in most new devices and has removed an older barrier to implantation in patients likely to need future imaging.

Market Limiters

Market Saturation

One of the main limiters in the global pacemaker market is saturation in developed regions. In many mature healthcare systems, pacemaker penetration is already high and most patients who clearly need pacing therapy have already received a device. This means annual procedure growth is not driven by a large rise in first-time implants. Instead, it comes mainly from replacement procedures, aging demographics and technology upgrades.

This is still enough to support healthy market growth, especially when premium technologies are expanding. However, it does mean that many developed markets are not expected to see dramatic increases in total implant volume. Growth in these regions is more incremental and value driven.

Commoditization

Commoditization is another important limiter, especially in standard transvenous pacing. Most transvenous systems now offer similar performance, similar longevity and similar core features across major manufacturers. This reduces meaningful differentiation and puts downward pressure on pricing, especially in markets shaped by tenders, large hospital groups and centralized procurement.

Leadless systems create a premium segment and help offset this problem, but most of the transvenous market remains a high-volume, lower-margin category. This keeps pricing flexibility limited and forces manufacturers to rely on service, brand trust, installed base and incremental feature differences rather than large product separation.

Recalls

Recent recalls have also added pressure to the market. Over the past several years, notable pacemaker recalls have increased regulatory attention and physician caution. Boston Scientific issued multiple Class I recalls affecting parts of its ACCOLADE family in 2024 and 2025, which influenced replacement activity and added oversight complexity. Abbott also issued Class II recalls and safety corrections involving AVEIR leadless systems in 2024 and 2025, primarily handled through software updates and revised programming workflows.

These events do not change the long-term need for pacing therapy, but they do create short-term pressure by increasing regulatory scrutiny, reinforcing physician caution and complicating market perception in a category where reliability is especially important.

Market Coverage and Data Scope

Quantitative Coverage

Market size, market shares, market forecasts, market growth rates, units sold and average selling prices.

Qualitative Coverage

Market drivers and limiters, growth trends, recent mergers and acquisitions, company profiles, product portfolios and leading competitors.

Time Frame

Base year 2025, historical data to 2022 and forecasts through 2032.

Data Types Included

Unit sales, average selling prices, procedure numbers, market size and growth trends.

This report is designed to support strategic planning, competitive benchmarking and commercial positioning by combining detailed pacing market data with practical analysis of technology adoption and market structure.

Markets Covered and Segmentation

• The report covers the Global Pacemaker Market, further segmented into:

Single-Chamber Pacemaker Market

This segment includes traditional transvenous single-chamber devices as well as single-chamber leadless pacemakers.

Dual-Chamber Pacemaker Market

This segment includes traditional transvenous dual-chamber systems as well as emerging dual-chamber leadless pacemakers.

Each segment is analyzed by unit sales, average selling prices and total market value, with forecasts through 2032 and historical data to 2022. This segmentation captures the major structural divide in the market between chamber configuration and between conventional and leadless pacing approaches.

Competitive Analysis

Medtronic held the largest global share in the pacemaker market in 2025 and continues to lead across all major segments. Its strength is supported by a deep clinical evidence base, strong physician familiarity and a broad lineup that includes Azure, Advisa MRI SureScan, Adapta and Attesta. Medtronic also remains the dominant player in leadless pacing through the Micra family, which continues to be the most widely adopted platform globally. Supported by extensive registry data, high procedural uptake and strong projected battery performance, Micra remains one of the biggest reasons Medtronic continues to lead the market. The company's continued investment in physiologic pacing and device longevity also strengthens its long-term position.

Abbott ranked second globally and remains a strong competitor through its Assurity MRI and Endurity platforms, along with its growing leadless portfolio. The AVEIR VR leadless pacemaker was an important milestone because it made Abbott the second major player to enter the leadless pacing segment. Since then, the AVEIR DR dual-chamber leadless system has become a major strategic growth platform. As the first modular dual-chamber leadless solution capable of direct atrial and ventricular communication, it positions Abbott strongly in one of the most important emerging areas of pacing. Early adoption and expanding approvals support the view that AVEIR DR will be a significant contributor to Abbott's future market share growth.

Boston Scientific held the third-leading position in the global market. Its pacing portfolio includes ACCOLADE and ESSENTIO MRI-compatible systems, as well as legacy platforms such as VITALIO, ADVANTIO and INGENIO. While Boston Scientific does not currently participate in leadless pacing, it maintains a meaningful role in conventional transvenous pacing and continues refining its portfolio through diagnostics, device longevity improvements and support for more physiologic pacing strategies. Its conventional product families remain important contributors to the company's broader CRM business.

Technology and Practice Trends

One of the most important trends in the pacemaker market is the rapid rise of leadless pacing. Single-chamber leadless devices are already taking share from standard single-chamber pacemakers, and dual-chamber leadless systems are creating a new premium growth segment.

Conduction system pacing is another major trend. His bundle pacing and left bundle branch area pacing are helping shift clinical practice toward more physiologic pacing methods and away from traditional right ventricular pacing in selected patients.

Remote monitoring is also becoming central to the value proposition of modern pacemakers. Automatic transmission of rhythm and device data supports more efficient follow-up and stronger long-term patient management.

Finally, software and diagnostics are becoming more sophisticated. AI-assisted analysis, better programming tools and more integrated data platforms are making pacing systems more valuable to both physicians and health systems.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

133 pages of detailed market analysis, segmentation and forecast data.

Methodology Appendix and Acronym Glossary.

Why This Report

Where are the strongest growth opportunities in the global pacemaker market through 2032?

How quickly are leadless pacing and conduction system pacing changing the structure of the market?

What role do remote monitoring, battery life and software improvements play in future device value?

How do saturation, commoditization and procurement pressure affect the outlook for standard transvenous pacing?

Which competitors are best positioned in transvenous and leadless pacing, and how durable are their advantages?

How can suppliers, investors and strategy teams evaluate opportunity in one of the most established but still evolving CRM markets?

The Global Pacemaker Market Report from iData Research answers these questions with detailed market sizing, pricing analysis, segmentation and competitive intelligence. Use it to benchmark competitors, understand technology-driven growth and support strategy in a large and increasingly premiumized pacing market.

TABLE OF CONTENT

List Of Figures

List Of Charts

Research Methodology

• Step 1: Project Initiation & Team Selection
• Step 2: Prepare Data Systems And Perform Secondary Research
• Step 3: Preparation For Interviews & Questionnaire Design
• Step 4: Performing Primary Research
• Step 5: Research Analysis: Establishing Baseline Estimates
• Step 6: Market Forecast And Analysis
• Step 7: Identify Strategic Opportunities
• Step 8: Final Review And Market Release
• Step 9: Customer Feedback And Market Monitoring

Impact Of Global Tariffs

• 4.1.1 Global Pacemaker Market Overview
• 4.1.2 Competitive Analysis
• 4.1.3 Procedures Included
• 4.1.4 Markets Included
• 4.1.5 Regions Included

Introduction

• 4.1.6 Transvenous Pacemakers
• 4.1.7 Leadless Pacemakers
• 4.1.8 Technological Advances In Pacemakers
• 4.1.9 Initial Placement And Replacement Of Pacemakers

Procedure Numbers

• 4.1.10 Total Pacemaker Placement Procedures
• 4.1.11 Initial Placement Pacemaker Procedures
• 4.1.12 Replacement Pacemaker Procedures
• 4.1.13 Leadless Pacemaker Procedures

Market Overview

• 4.1.14 By Segment
• 4.1.15 By Region

Market Analysis And Forecast

• 4.1.16 Total Pacemaker Market
• 4.1.2 Standard Single-Chamber Pacemaker Market
  • 4.1.2.1 Initial Placement Single-Chamber Pacemaker Market
  • 4.1.2.2 Replacement Single-Chamber Pacemaker Market
• 4.1.3 Leadless Single-Chamber Pacemaker Market
• 4.1.4 Standard Dual-Chamber Pacemaker Market
  • 4.1.4.1 Initial Placement Standard Dual-Chamber Pacemaker Market
  • 4.1.4.2 Replacement Standard Dual-Chamber Pacemaker Market
• 4.1.1 Leadless Dual-Chamber Pacemaker Market

Drivers And Limiters

• 4.1.2 Market Drivers
• 4.1.3 Market Limiters

Competitive Market Share Analysis

Abbreviations

LIST OF CHARTS

• Chart 4-1: Pacemaker Market, Global, 2022 - 2032
• Chart 4-2: Pacemaker Placement Procedures, Global, 2025
• Chart 4-3: Pacemaker Placement Procedures by Segment, Global, 2022 - 2032
• Chart 4-4: Pacemaker Market by Segment, Global, 2022 - 2032
• Chart 4-5: Pacemaker Market by Region, Global, 2022 - 2032
• Chart 4-6: Leading Competitors, Pacemaker Market, Global, 2025

LIST OF FIGURES

• Figure 4-1: Pacemaker Procedures Covered
• Figure 4-2: Pacemaker Markets Covered
• Figure 4-3: Pacemaker Regions Covered, Global (1 of 2)
• Figure 4-4: Pacemaker Regions Covered, Global (2 of 2)
• Figure 4-5: Pacemaker Placement Procedures by Segment, Global, 2022 - 2032
• Figure 4-6: Pacemaker Placement Procedures by Region, Global, 2022 - 2032
• Figure 4-7: Pacemaker Placement Procedures by Country, North America, 2022 - 2032
• Figure 4-8: Pacemaker Placement Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 4-9: Pacemaker Placement Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 4-10: Pacemaker Placement Procedures by Country, Western Europe, 2022 - 2032
• Figure 4-11: Pacemaker Placement Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 4-12: Pacemaker Placement Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 4-13: Pacemaker Placement Procedures by Country, Middle East, 2022 - 2032
• Figure 4-14: Pacemaker Placement Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 4-15: Pacemaker Placement Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 4-16: Pacemaker Placement Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 4-17: Pacemaker Placement Procedures by Country, Africa, 2022 - 2032
• Figure 4-18: Initial Placement Pacemaker Procedures by Region, Global, 2022 - 2032
• Figure 4-19: Initial Placement Pacemaker Procedures by Country, North America, 2022 - 2032
• Figure 4-20: Initial Placement Pacemaker Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 4-21: Initial Placement Pacemaker Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 4-22: Initial Placement Pacemaker Procedures by Country, Western Europe, 2022 - 2032
• Figure 4-23: Initial Placement Pacemaker Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 4-24: Initial Placement Pacemaker Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 4-25: Initial Placement Pacemaker Procedures by Country, Middle East, 2022 - 2032
• Figure 4-26: Initial Placement Pacemaker Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 4-27: Initial Placement Pacemaker Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 4-28: Initial Placement Pacemaker Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 4-29: Initial Placement Pacemaker Procedures by Country, Africa, 2022 - 2032
• Figure 4-30: Replacement Pacemaker Procedures by Region, Global, 2022 - 2032
• Figure 4-31: Replacement Pacemaker Procedures by Country, North America, 2022 - 2032
• Figure 4-32: Replacement Pacemaker Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 4-33: Replacement Pacemaker Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 4-34: Replacement Pacemaker Procedures by Country, Western Europe, 2022 - 2032
• Figure 4-35: Replacement Pacemaker Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 4-36: Replacement Pacemaker Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 4-37: Replacement Pacemaker Procedures by Country, Middle East, 2022 - 2032
• Figure 4-38: Replacement Pacemaker Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 4-39: Replacement Pacemaker Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 4-40: Replacement Pacemaker Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 4-41: Replacement Pacemaker Procedures by Country, Africa, 2022 - 2032
• Figure 4-42: Leadless Pacemaker Procedures by Region, Global, 2022 - 2032
• Figure 4-43: Leadless Pacemaker Procedures by Country, North America, 2022 - 2032
• Figure 4-44: Leadless Pacemaker Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 4-45: Leadless Pacemaker Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 4-46: Leadless Pacemaker Procedures by Country, Western Europe, 2022 - 2032
• Figure 4-47: Leadless Pacemaker Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 4-48: Leadless Pacemaker Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 4-49: Leadless Pacemaker Procedures by Country, Middle East, 2022 - 2032
• Figure 4-50: Leadless Pacemaker Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 4-51: Leadless Pacemaker Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 4-52: Leadless Pacemaker Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 4-53: Leadless Pacemaker Procedures by Country, Africa, 2022 - 2032
• Figure 4-54: Pacemaker Market by Segment, Global, 2022 - 2032 (US$M)
• Figure 4-55: Pacemaker Market by Region, Global, 2022 - 2032 (US$M)
• Figure 4-56: Pacemaker Market, Global, 2022 - 2032
• Figure 4-57: Units Sold by Region, Pacemaker Market, Global, 2022 - 2032
• Figure 4-58: Average Selling Price by Region, Pacemaker Market, Global, 2022 - 2032 (US$)
• Figure 4-59: Market Value by Region, Pacemaker Market, Global, 2022 - 2032 (US$M)
• Figure 4-60: Standard Single-Chamber Pacemaker Market by Segment, Global, 2022 - 2032 (US$M)
• Figure 4-61: Standard Single-Chamber Pacemaker Market, Global, 2022 - 2032
• Figure 4-62: Units Sold by Region, Standard Single-Chamber Pacemaker Market, Global, 2022 - 2032
• Figure 4-63: Average Selling Price by Region, Standard Single-Chamber Pacemaker Market, Global, 2022 - 2032 (US$)
• Figure 4-64: Market Value by Region, Standard Single-Chamber Pacemaker Market, Global, 2022 - 2032 (US$M)
• Figure 4-65: Initial Placement Standard Single-Chamber Pacemaker Market, Global, 2022 - 2032
• Figure 4-66: Units Sold by Region, Initial Placement Standard Single-Chamber Pacemaker Market, Global, 2022 - 2032
• Figure 4-67: Average Selling Price by Region, Initial Placement Standard Single-Chamber Pacemaker Market, Global, 2022 - 2032 (US$)
• Figure 4-68: Market Value by Region, Initial Placement Standard Single-Chamber Pacemaker Market, Global, 2022 - 2032 (US$M)
• Figure 4-69: Replacement Standard Single-Chamber Pacemaker Market, Global, 2022 - 2032
• Figure 4-70: Units Sold by Region, Replacement Standard Single-Chamber Pacemaker Market, Global, 2022 - 2032
• Figure 4-71: Average Selling Price by Region, Replacement Standard Single-Chamber Pacemaker Market, Global, 2022 - 2032 (US$)
• Figure 4-72: Market Value by Region, Replacement Standard Single-Chamber Pacemaker Market, Global, 2022 - 2032 (US$M)
• Figure 4-73: Leadless Single-Chamber Pacemaker Market, Global, 2022 - 2032
• Figure 4-74: Units Sold by Region, Leadless Single-Chamber Pacemaker Market, Global, 2022 - 2032
• Figure 4-75: Average Selling Price by Region, Leadless Single-Chamber Pacemaker Market, Global, 2022 - 2032 (US$)
• Figure 4-76: Market Value by Region, Leadless Single-Chamber Pacemaker Market, Global, 2022 - 2032 (US$M)
• Figure 4-77: Standard Dual-Chamber Pacemaker Market, Global, 2022 - 2032
• Figure 4-78: Units Sold by Region, Standard Dual-Chamber Pacemaker Market, Global, 2022 - 2032
• Figure 4-79: Average Selling Price by Region, Standard Dual-Chamber Pacemaker Market, Global, 2022 - 2032 (US$)
• Figure 4-80: Market Value by Region, Standard Dual-Chamber Pacemaker Market, Global, 2022 - 2032 (US$M)
• Figure 4-81: Initial Placement Standard Dual-Chamber Pacemaker Market, Global, 2022 - 2032
• Figure 4-82: Units Sold by Region, Initial Placement Standard Dual-Chamber Pacemaker Market, Global, 2022 - 2032
• Figure 4-83: Average Selling Price by Region, Initial Placement Standard Dual-Chamber Pacemaker Market, Global, 2022 - 2032 (US$)
• Figure 4-84: Market Value by Region, Initial Placement Standard Dual-Chamber Pacemaker Market, Global, 2022 - 2032 (US$M)
• Figure 4-85: Replacement Standard Dual-Chamber Pacemaker Market, Global, 2022 - 2032
• Figure 4-86: Units Sold by Region, Replacement Standard Dual-Chamber Pacemaker Market, Global, 2022 - 2032
• Figure 4-87: Average Selling Price by Region, Replacement Standard Dual-Chamber Pacemaker Market, Global, 2022 - 2032 (US$)
• Figure 4-88: Market Value by Region, Replacement Standard Dual-Chamber Pacemaker Market, Global, 2022 - 2032 (US$M)
• Figure 4-89: Leadless Dual-Chamber Pacemaker Market, Global, 2022 - 2032
• Figure 4-90: Units Sold by Region, Leadless Dual-Chamber Pacemaker Market, Global, 2022 - 2032
• Figure 4-91: Average Selling Price by Region, Leadless Dual-Chamber Pacemaker Market, Global, 2022 - 2032 (US$)
• Figure 4-92: Market Value by Region, Leadless Dual-Chamber Pacemaker Market, Global, 2022 - 2032 (US$M)
• Figure 4-93: Leading Competitors, Pacemaker Market, Global, 2025
• Figure 4-94: Leading Competitors by Region, Single-Chamber Pacemaker Market, Global, 2025
• Figure 4-95: Leading Competitors by Region, Dual-Chamber Pacemaker Market, Global, 2025